Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02971397 | Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 40 | Wake Forest University Health SciencesOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03269422 | Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL) | completed | Phase 1 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06532032 | A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer(swalloWTail) | completed | Phase 1 / Phase 2 | 12 | Janssen Research & Development, LLCINDUSTRY | 4 | Jul 31, 2026 | clinicaltrials |
| NCT02718066 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 96 | HUYABIO International, LLC.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03259503 | Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant | completed | Phase 1 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03713580 | Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma | completed | Phase 1 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04290546 | CIML NK Cell in Head & Neck Cancer | completed | Phase 1 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07040943 | Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors. | completed | Phase 1 | 6 | West China HospitalOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05037149 | Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors | completed | Phase 1 | 50 | SirnaomicsINDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03030066 | Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas | completed | Phase 1 | 47 | Daiichi SankyoINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03581487 | Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT00429312 | A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma | completed | Phase 1 / Phase 2 | 10 | Jennerex BiotherapeuticsINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05278975 | Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma | completed | Phase 1 / Phase 2 | 50 | RS Oncology LLCINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06614140 | Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 8 | Seqker Biosciences, Inc.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03374332 | Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 11 | Brown UniversityOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03410030 | Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)(AA NABPLAGEM) | completed | Phase 1 / Phase 2 | 17 | HonorHealth Research InstituteOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03586661 | Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05034627 | Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 1 | 15 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04864418 | AST-021p Study in Advanced Solid Tumors | completed | Phase 1 | 22 | Aston Sci. Inc.INDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04826341 | A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors | completed | Phase 1 / Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04919369 | All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 | 18 | Dwight OwenOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05770310 | A Phase I Study Of JS015 in Patients With Advanced Solid Tumors | completed | Phase 1 | 12 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03383302 | SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects(STILE) | completed | Phase 1 / Phase 2 | 36 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05024045 | Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | completed | Phase 1 | 27 | Eli Lilly and CompanyINDUSTRY | 4 | Jul 17, 2026 | clinicaltrials |
| NCT05740202 | A Trial of SHR-7367 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 22 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07300202 | A Phase I, Single-arm, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers | completed | Phase 1 | 15 | Oriplantee Company LimitedOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04374877 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | completed | Phase 1 | 145 | Coherus Oncology, Inc.INDUSTRY | 3 | Jul 15, 2026 | clinicaltrials |
| NCT05396300 | A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors | completed | Phase 1 | 58 | Weijia Fang, MDOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06307093 | Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms | completed | Phase 1 | 90 | R-PharmINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02481635 | A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 11 | University Health Network, TorontoOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04037254 | Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring | completed | Phase 1 / Phase 2 | 22 | NRG OncologyOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05538195 | Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors | completed | Phase 1 / Phase 2 | 17 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06470763 | A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) | completed | Phase 1 / Phase 2 | 63 | Anaveon AGINDUSTRY | 7 | Jul 10, 2026 | clinicaltrials |
| NCT02009449 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors(IVY) | completed | Phase 1 | 353 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT03283917 | Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis | completed | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05415475 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors | completed | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06464965 | Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer | completed | Phase 1 | 9 | Zhejiang Provincial People's HospitalOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT01380600 | Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma | completed | Phase 1 | 15 | Jennerex BiotherapeuticsINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04487756 | Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer(VENEZO-LUNG) | completed | Phase 1 / Phase 2 | 20 | Instituto Oncológico Dr RosellOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04685473 | Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors | completed | Phase 1 | 24 | Taivex Therapeutics CorporationINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04773951 | A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors | completed | Phase 1 | 47 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06049966 | Atezolizumab in Large Cell Neuroendocrine Carcinoma(LANCE) | completed | Phase 1 | 22 | Oncology Center of Biochemical Education And ResearchOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06115902 | A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer | completed | Phase 1 | 153 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05751486 | A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma | completed | Phase 1 | 64 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06153238 | A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma | completed | Phase 1 | 322 | SandozINDUSTRY | 18 | Jul 7, 2026 | clinicaltrials |
| NCT06403436 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors(TT-CSP-001) | completed | Phase 1 | 45 | TOLREMO therapeutics AGINDUSTRY | 3 | Jul 7, 2026 | clinicaltrials |
| NCT03491709 | A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC | completed | Phase 1 | 18 | Dragonboat Biopharmaceutical Company LimitedINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04106856 | Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer(SHAPER) | completed | Phase 1 | 22 | University of UtahOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04739111 | An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor | completed | Phase 1 | 12 | Dragonboat Biopharmaceutical Company LimitedINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 3, 2026source: clinicaltrials